PerELISA: overexpression of 13 genes associated with endocrine sensitivity in HR+/HER2+ BC

HRD, RB-loss gene sig, intrinsic subtype and response to neoadjuvant treatment in HR+/HER2- early BCПодробнее

postMONARCHE: abemaciclib + fulvestrant in HR+/HER2- MBC following CDK4/6i & endocrine therapyПодробнее

TAKTIC: ipatasertib, endocrine therapy and CDK4/6i for patients with HR+/HER2- mBCПодробнее

Palbociclib, pembrolizumab, and endocrine therapy in HR+/HER2- breast cancerПодробнее

monarchE: adjuvant abemaciclib + endocrine therapy in patients with HR+, HER2- high-risk eBCПодробнее

MonarchE 4-year: abemaciclib + endocrine therapy for HR+, HER2-, node-positive, high-risk early BCПодробнее

The HER Pathway and CancerПодробнее

Dr. Hershman on the Use of Endocrine Therapy in Premenopausal HR+/HER2- Breast CancerПодробнее

Discover the LSP1 gene, its mutation, and its intriguing connection to breast cancer.Подробнее

Adding ribociclib to endocrine therapy shows an improvement in invasive DFS in HR+/HER2 BC patientsПодробнее

Poziotinib for HER2-positive metastatic breast cancerПодробнее

ADAPT trial: Endocrine + ribociclib vs. chemotherapy in HR+/HER2- early breast cancerПодробнее

PENELOPE-B: palbociclib with endocrine therapy in HR+, HER2-negative breast cancerПодробнее

Evo-Ed: Breast Cancer and the HER2 GeneПодробнее

Raising the Bar in HR+/HER2- Early Breast Cancer: CDK4 and 6 InhibitorsПодробнее

Endocrine Resistance-Causing Genes in Breast Cancer | OncotargetПодробнее

N9831 trial: genes associated with early and late recurrence in HER2+ breast cancerПодробнее

MONARCH 3: Abemaciclib as initial therapy for patients with HR /HER2- advanced breast cancerПодробнее